Could a diabetes drug tame Alzheimer's inflammation?

NCT ID NCT05891496

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether semaglutide, a medicine used for diabetes and weight loss, can reduce inflammation in the brain and body of people with early Alzheimer's disease. Twenty-three participants with mild memory problems or mild dementia received either semaglutide or a placebo for 12 weeks, then all received semaglutide for another 52 weeks. The goal was to see how the drug affects immune system activity, not to cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMERS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMERS DISEASE

Contacts and locations

Locations

Azienda Ospedaliera Spedali Civili di Brescia

Brescia, 25123, Italy
Azienda Ospedaliera di Perugia;Ospedale S. Maria della Miser

Perugia, 06132, Italy
Banner Sun Health Research Institute

Sun City, Arizona, 85351, United States
Brain Matters Research

Delray Beach, Florida, 33445, United States
Centre de la Mémoire

Geneva, 1205, Switzerland
Fondazione Santa Lucia IRCCS

Roma, 00179, Italy
Karolinska Universitetssjukhuset, Huddinge

Stockholm, 141 86, Sweden
Memory Program

Toronto, Ontario, M3B2S7, Canada
Ottawa Memory Clinic

Ottawa, Ontario, K1Z 1G3, Canada
Rigshospitalet - afsnit 8015

København Ø, 2100, Denmark
Rigshospitalet - afsnit 8015 Hukommelsesklinikken

København Ø, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.